€1.96
Your prediction
BioInvent International AB Stock
Pros and Cons of BioInvent International AB in the next few years
Pros
Cons
Performance of BioInvent International AB vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| BioInvent International AB | -1.900% | 12.360% | 40.252% | -17.355% | 21.951% | -58.678% | -33.222% |
| NeuroVive Pharmaceutical AB | 7.140% | -46.154% | -41.667% | -59.615% | -65.854% | -92.821% | -96.250% |
| India Globalization Capital | -6.440% | -19.200% | 41.259% | 44.286% | 54.198% | -68.388% | -68.923% |
| Celsion Corp. | 0.810% | -17.568% | 49.693% | 11.927% | 65.986% | -91.393% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.BioInvent, a biotechnology and medical research company, appears to be in a challenging financial situation based on the provided data. Total assets have been growing year-over-year which indicate positive strides in the company's performance. However, the company has been reporting consistent net losses which raise concerns regarding its financial health. To gain a comprehensive understanding of BioInvent's financial standing, let's dive into the details and explore the pros and cons of the company's financials.
*Pros: *
Growing Total Assets: BioInvent's total assets have been steadily increasing from SEK 802,640,000 in 2020 to SEK 1,712,214,000 in 2022. This growth indicates that the company has been expanding its resources and investing in its business.